Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Muqdad Zuriqat

Sherman, TX Medical Doctor

NPI 1417962887 CMS profile 154410

300 N Highland Ave, Suite 455, Sherman, TX 75092

Open in the dashboard

General payments

$14,263

857 records reported · program years 2019–2025

Research payments

$415

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,366,117 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Muqdad Zuriqat of Sherman, TX is reported in the CMS Open Payments database as having received $14,263 across 857 general payments and $415 in research payments paid to them. Separately, studies naming them as principal investigator received $1,366,117 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,971 164
2024 General $2,766 155
2023 General $1,874 100
2022 General $1,967 117
2021 General $1,841 118
2020 General $1,479 97
2019 General $1,365 106
2019 Research $415 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Muqdad Zuriqat
  • Texas median
  • Middle half of Texas
  • National median

In program year 2025, general payments to Muqdad Zuriqat were reported at $2,971. Among 86,592 Texas profiles paid that year, the median was $188 and the middle half received between $55 and $669.

Show as a table
Year Muqdad Zuriqat Texas median Middle half National median
2019 $1,365 $191 $56–$744 $163
2020 $1,479 $125 $38–$452 $114
2021 $1,841 $150 $43–$543 $132
2022 $1,967 $169 $50–$606 $149
2023 $1,874 $183 $53–$639 $160
2024 $2,766 $188 $55–$666 $164
2025 $2,971 $188 $55–$669 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,913 215 payments
  2. AstraZeneca Pharmaceuticals LP $2,555 119 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,133 77 payments
  4. Mylan Specialty L.P. $994 76 payments
  5. Actelion Pharmaceuticals US, Inc. $965 48 payments
  6. Genzyme Corporation $680 31 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $651 42 payments
  8. United Therapeutics Corporation $516 27 payments
  9. Baxter Healthcare $442 25 payments
  10. Insmed, Inc. $433 30 payments
  11. Other $2,980 167 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,127 852 payments
  2. Education $136 5 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,807 139 payments
  2. BREZTRI $1,127 42 payments
  3. UPTRAVI $864 43 payments
  4. FASENRA $751 19 payments
  5. YUPELRI $747 48 payments
  6. NUCALA $740 46 payments
  7. DUPIXENT $702 32 payments
  8. OPSUMIT $594 32 payments
  9. SYMBICORT $560 32 payments
  10. AIRSUPRA $504 14 payments
  11. Other $8,137 508 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $415 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

6,447

Median for Pulmonary Disease: 936

Drug cost

$2,682,023

Median for Pulmonary Disease: $487,987

Branded share of claims

59.1%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 1,159 $872,925
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 332 $234,667
Ofev Nintedanib Esylate Brand 17 $218,468
Prolastin C Alpha-1-Proteinase Inhibitor Brand 17 $215,787
Spiriva Respimat Tiotropium Bromide Brand 214 $166,905
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 39 $140,557
Dupixent Syringe Dupilumab Brand 29 $119,606
Xolair Omalizumab Brand 32 $115,248
Breo Ellipta Fluticasone/Vilanterol Brand 164 $95,775
Aralast Np Alpha-1-Proteinase Inhibitor Brand 14 $80,444

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$677,441

Of which drugs: $46

Medicare patients

1,240

Average age 74

Services billed

10,260

654 women, 586 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 64%
Arthritis 58%
Ischemic heart disease 51%
Heart failure 41%
Diabetes 40%
Atrial fibrillation 36%
Chronic kidney disease 35%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 31 157 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$497 1,159 —
DUPIXENT
$301 29 —
AIRSUPRA
$262 — —
GLASSIA
$200 — —
XOLAIR
$196 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

858 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record